#BCAB

StockTitan

@stocktitan.net

1 week ago

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets BioAtla (NASDAQ: BCAB) announced that its Board has launched a formal review of strategic options to maximize shareholder value, including potential sales, licensing, partnerships or other transactions. The Company simultaneously is executing a restructuring to cut operating expenses, including a workforce reduction of about 70%, and retained Tungsten Advisors as exclusive strategic financial advisor.BioAtla said there is no assurance the process will produce a transaction and it does not intend to provide updates unless the Board approves an action or disclosure becomes appropriate.

#BCAB BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

www.stocktitan.net/news/BCAB/bio-atla-annou...

Small Cap Strategist

@smcapstrategist.bsky.social

2 months ago

Small-cap stocks in new downtrend according to average directional index, Wed Jan 7th - #WACD #STAA #PAYS #NEXT #MVBF #BCAB #ANGO #VET #OSG #MBI #GSBD #FBRT #BOW - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

4 months ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress BioAtla (Nasdaq: BCAB) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company achieved FDA alignment on a planned randomized Phase 3 Oz-V trial in 2L+ OPSCC with dual primary endpoints (overall response rate and overall survival) and potential accelerated approval. BA3182 (CAB-EpCAM x CAB-CD3-TCE) dose escalation showed a confirmed partial response ongoing >6 months and a Phase 1 readout is expected in H1 2026. Mecbotamab vedotin (Mec-V) showed median OS 21.5 months in 44 evaluable soft tissue sarcoma patients. Q3 results: R&D $9.5M, G&A $4.2M, net loss $15.8M, cash $8.3M and a recent $2.0M milestone payment.

#BCAB BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

www.stocktitan.net/news/BCAB/bio-atla-repor...

StockTitan

@stocktitan.net

4 months ago

#BCAB BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

www.stocktitan.net/news/BCAB/bio-atla-s-mec...

StockTitan

@stocktitan.net

4 months ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 BioAtla (Nasdaq: BCAB) will announce its third quarter 2025 financial results and provide business highlights on Thursday, November 13, 2025. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results for the quarter ended September 30, 2025. Investors can access the live webcast via the company website and dial in domestically at (800) 343-4136 or internationally at (203) 518-9843 using Conference ID BIOATLA.The press release with financial results will be posted in News Releases prior to the call, and a replay will be available under Events & Presentations in the Investors section of the website.

#BCAB BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

www.stocktitan.net/news/BCAB/bio-atla-to-an...

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Small-cap stocks with strong volume declines, Tue Oct 14th - #PFAI #OP #NEXM #HVII #SEED #QH #BYND #BCRX #BCAB #ALBT #SOJD #OEC #NMG - More: crystalequityresearch.com/trade-alerts... - #smallcap

StockTitan

@stocktitan.net

7 months ago

Clinical-Stage Biotech BioAtla Sets Q2 Earnings Date: Key Updates on CAB Cancer Therapeutics Expected Clinical-stage biotech BioAtla announces Q2 2025 earnings webcast featuring updates on CAB solid tumor therapeutics pipeline. Join live discussion August 7. Get details.

#BCAB BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

www.stocktitan.net/news/BCAB/bio-atla-to-an...

StockTitan

@stocktitan.net

7 months ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company, will present at the 2025 ESMO TAT Asia Meeting in Hong Kong from July 18-20, 2025. The company will deliver an oral presentation about their first-in-human phase I study of BA3182, a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager for treating refractory metastatic adenocarcinoma.The presentation will be given by Jennifer B. Brooke Valerin on July 18, 2025 at 15:59-16:06 GMT+8. The presentation materials will be available on BioAtla's website after the event.

#BCAB BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

www.stocktitan.net/news/BCAB/bio-atla-annou...

StockTitan

@stocktitan.net

10 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress BioAtla (NASDAQ: BCAB) reported its Q1 2025 financial results and clinical progress. Key highlights include: CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 study has dosed first three patients at 300 micrograms, with data expected mid-2025. Mecbotamab vedotin showed exceptional 2-year survival rate of 59% in mKRAS non-small cell lung cancer, significantly outperforming standard care's typical Ozuriftamab vedotin demonstrated strong results in HPV+ head and neck cancer with 100% disease control rate and 45% overall response rate. Financially, R&D expenses decreased to $12.4M from $18.9M YoY, while net loss improved to $15.3M from $23.2M. Cash position stands at $32.4M as of March 31, 2025, expected to fund operations through key clinical readouts in 1H 2026.

#BCAB BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

www.stocktitan.net/news/BCAB/bio-atla-repor...

StockTitan

@stocktitan.net

10 months ago

Cancer Treatment Breakthrough: BioAtla's Novel Drug Outperforms Standard Therapy in Multiple Cancers New data reveals BioAtla's CAB technology surpasses existing cancer treatments in efficacy tests. Exclusive AACR 2025 presentation details groundbreaking results. See full data.

#BCAB BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

www.stocktitan.net/news/BCAB/bio-atla-annou...

StockTitan

@stocktitan.net

10 months ago

New Phase 2 Cancer Drug Data: BioAtla's Head and Neck Cancer Treatment Results at ASCO 2025 Latest Phase 2 trial results for ozuriftamab in treating advanced head and neck cancer. New efficacy data from BioAtla's innovative ROR2-ADC therapy. See findings.

#BCAB BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

www.stocktitan.net/news/BCAB/bio-atla-annou...

StockTitan

@stocktitan.net

11 months ago

BioAtla's Breakthrough: 66% Survival Rate in Lung Cancer Trial Amid Strategic Cost Reductions New data reveals exceptional survival rates in lung cancer trial while reducing R&D costs by 49%. Strategic restructuring extends cash runway beyond key 2026 milestones.

#BCAB BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

www.stocktitan.net/news/BCAB/bio-atla-repor...

StockTitan

@stocktitan.net

11 months ago

BioAtla Earnings Alert: Key Q4 and 2024 Results Coming March 27 - What to Watch Clinical-stage biotech BioAtla will discuss CAB antibody therapeutics progress and financial performance. Join the conference call on March 27 at 4:30 PM ET.

#BCAB BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

www.stocktitan.net/news/BCAB/bio-atla-to-an...

StockTitan

@stocktitan.net

1 year ago

BioAtla Secures $9.2M Funding Through Strategic Stock Offering to Advance Clinical Programs BioAtla raises capital through registered direct offering to accelerate development of key clinical programs, with major data readouts expected in 2025-2026.

#BCAB BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

www.stocktitan.net/news/BCAB/bio-atla-inc-a...

StockTitan

@stocktitan.net

1 year ago

BioAtla to Present Breakthrough Cancer Treatment Data at Major IASLC 2024 Conference BioAtla will showcase clinical outcomes of Mecbotamab Vedotin in advanced NSCLC patients at prestigious IASLC 2024 meeting. Key findings on KRAS mutations to be revealed.

#BCAB BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

#stocks #StockMarket #news

www.stocktitan.net/news/BCAB/bio-atla-annou...

InsiderFinance

@insiderfinance.com

1 year ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#DNN, #RL, #BCAB, #ED, #BRZE

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

1 year ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GCT, #BCAB, #JD, #QCOM, #RL

#OptionFlow #OptionsTrading #Trading

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #BCAB ) BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #BCAB ) BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

#StockMarket #News